Overview
Codexis develops and licenses biocatalysts created through protein engineering to enable the production of pharmaceuticals and fine chemicals. Its core products are engineered enzymes (biocatalysts) that speed up or enable chemical reactions in manufacturing, often enabling processes that are more cost-effective and sustainable than traditional methods. The biocatalysts can be used as ready-to-use products or via custom enzyme development services tailored to a customer's process, with licensing and service contracts generating revenue. Unlike traditional chemical catalysts, Codexis focuses on designing enzymes that work under specific industrial conditions to improve efficiency and reduce waste. The company aims to transform conventional manufacturing by providing scalable, enzyme-based solutions that shorten development times and lower environmental impact.
Work here?Claim your company
Simplify's take
What believers are saying
- Q3 2026 revenue hit $19.3 million, up from $8.6 million last year.
- Product gross margin rose to 74.5% in Q3 2026 from 64%.
- Codexis expects ECO GMP retrofit construction in 2027, expanding siRNA supply capacity.
What critics are saying
- Codexis still posted an $8.1 million Q3 2026 net loss.
- The $60 million term loan refinanced debt, adding leverage to a fragile balance sheet.
- ECO Synthesis adoption stalls, leaving Codexis dependent on low-margin enzyme sales and financing.
What makes Codexis unique
- Codexis’ ECO Synthesis reached 100-gram scale with 90%+ quality and halved cycle time.
- Three 2026 drug approvals used Codexis enzymes, validating customer adoption in pharmaceuticals.
- The Trinity Capital loan and 2028 runway give Codexis time to commercialize siRNA.
Help us improve and share your feedback! Did you find this helpful?